Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2900) 2900
Book Review (557) 557
Publication (115) 115
Conference Proceeding (49) 49
Book Chapter (27) 27
Magazine Article (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
prasugrel (2158) 2158
index medicus (1916) 1916
humans (1825) 1825
clopidogrel (1816) 1816
cardiac & cardiovascular systems (1041) 1041
ticlopidine - analogs & derivatives (1035) 1035
ticagrelor (1031) 1031
male (929) 929
percutaneous coronary intervention (876) 876
platelet aggregation inhibitors - therapeutic use (866) 866
female (840) 840
prasugrel hydrochloride (838) 838
acute coronary syndromes (715) 715
middle aged (705) 705
aspirin (637) 637
aged (631) 631
treatment outcome (587) 587
ticlopidine - therapeutic use (586) 586
platelet aggregation inhibitors - adverse effects (501) 501
platelet aggregation inhibitors - administration & dosage (489) 489
acute coronary syndrome (483) 483
acute coronary syndrome - drug therapy (472) 472
adenosine - analogs & derivatives (459) 459
thiophenes - therapeutic use (454) 454
piperazines - therapeutic use (452) 452
antiplatelet therapy (435) 435
pharmacology & pharmacy (424) 424
peripheral vascular disease (399) 399
abridged index medicus (371) 371
hematology (355) 355
ticlopidine - administration & dosage (347) 347
risk factors (336) 336
purinergic p2y receptor antagonists - therapeutic use (327) 327
intervention (326) 326
ticlopidine - adverse effects (323) 323
coronary heart disease (319) 319
platelet inhibition (308) 308
myocardial-infarction (306) 306
platelet aggregation inhibitors - pharmacology (306) 306
blood platelets - drug effects (304) 304
inhibition (298) 298
platelet aggregation - drug effects (298) 298
cardiovascular (297) 297
adenosine - therapeutic use (288) 288
trial (287) 287
hemorrhage - chemically induced (284) 284
blood platelets (275) 275
thrombosis (270) 270
cardiac patients (268) 268
elevation myocardial-infarction (266) 266
platelet reactivity (258) 258
drug therapy, combination (254) 254
aggregation (250) 250
heart attacks (249) 249
drug therapy (248) 248
myocardial infarction (248) 248
piperazines - administration & dosage (248) 248
thiophenes - administration & dosage (246) 246
cardiology (244) 244
care and treatment (243) 243
piperazines - adverse effects (241) 241
thiophenes - adverse effects (241) 241
time factors (239) 239
outcomes (238) 238
stent thrombosis (229) 229
purinergic p2y receptor antagonists - administration & dosage (225) 225
artery-disease (217) 217
therapy (216) 216
stents (215) 215
prospective studies (214) 214
aspirin - therapeutic use (213) 213
platelet function tests (212) 212
adult (199) 199
double-blind (199) 199
platelets (199) 199
prasugrel hydrochloride - therapeutic use (197) 197
cangrelor (196) 196
acute coronary syndrome - therapy (194) 194
piperazines - pharmacology (193) 193
mortality (192) 192
purinergic p2y receptor antagonists - adverse effects (191) 191
medicine, general & internal (190) 190
thiophenes - pharmacology (188) 188
myocardial infarction - drug therapy (186) 186
transluminal angioplasty (182) 182
acute myocardial-infarction (180) 180
ticlopidine - pharmacology (179) 179
platelet aggregation inhibitors - pharmacokinetics (176) 176
analysis (171) 171
st-segment elevation (164) 164
dose-response relationship, drug (161) 161
reactivity (161) 161
blood platelets - metabolism (157) 157
cardiovascular disease (157) 157
active metabolite (154) 154
animals (153) 153
bleeding (153) 153
prasugrel hydrochloride - administration & dosage (153) 153
cardiovascular diseases (152) 152
p2y (150) 150
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2730) 2730
German (66) 66
French (38) 38
Spanish (33) 33
Italian (17) 17
Russian (17) 17
Polish (16) 16
Czech (11) 11
Japanese (10) 10
Turkish (10) 10
Korean (3) 3
Croatian (2) 2
Portuguese (2) 2
Chinese (1) 1
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Switching antiplatelet therapy in real-world clinical practice
by Angiolillo, Dominick J
Cardiovascular Revascularization Medicine, ISSN 1553-8389, 12/2018, Volume 19, Issue 8, pp. 897 - 898
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | ACADEMIC RESEARCH CONSORTIUM | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Bioindicators | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
by Wallentin, Lars
European Heart Journal, ISSN 0195-668X, 8/2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers
by Hobl, Eva-Luise and Reiter, Birgit and Schoergenhofer, Christian and Schwameis, Michael and Derhaschnig, Ulla and Lang, Irene Marthe and Stimpfl, Thomas and Jilma, Bernd
Clinical Research in Cardiology, ISSN 1861-0684, 4/2016, Volume 105, Issue 4, pp. 349 - 355
Morphine decreases the concentrations and effects of clopidogrel, which could lead to treatment failure in myocardial infarction.To clarify whether more potent... 
Prasugrel | Medicine & Public Health | Drug interactions | Morphine | Platelet function tests | Cardiology | Vasodilator-stimulated phosphoprotein | MORTALITY | PATHWAYS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHOSPHORYLATION | REPERFUSION | ACUTE CORONARY SYNDROMES | CLOPIDOGREL | PLATELET INHIBITION | ACUTE MYOCARDIAL-INFARCTION | INTERVENTION | ACTIVE METABOLITE | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Male | Purinergic P2Y Receptor Antagonists - blood | Drug Monitoring - methods | Healthy Volunteers | Platelet Aggregation Inhibitors - blood | Young Adult | Purinergic P2Y Receptor Antagonists - adverse effects | Tandem Mass Spectrometry | Austria | Analgesics, Opioid - adverse effects | Drug Interactions | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Chromatography, Liquid | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - administration & dosage | Prasugrel Hydrochloride - pharmacokinetics | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Risk Assessment | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Analgesics, Opioid - administration & dosage | Morphine - administration & dosage | Morphine - adverse effects | Prasugrel Hydrochloride - blood | Medical colleges | Metabolites | Vasodilators | Clinical trials | Liquid chromatography | Mass spectrometry | Index Medicus | Original Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
by Cuisset, Thomas and Deharo, Pierre and Quilici, Jacques and Johnson, Thomas W and Deffarges, Stephanie and Bassez, Clemence and Bonnet, Guillaume and Fourcade, Laurent and Mouret, Jean Philippe and Lambert, Marc and Verdier, Valentine and Morange, Pierre Emmanuel and Alessi, Marie Christine and Bonnet, Jean Louis
European Heart Journal, ISSN 0195-668X, 2017, Volume 38, Issue 41, pp. 3070 - 3078
Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However,... 
Switch | Acute coronary syndrome | P2Y12 blockers | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | TICAGRELOR | CLASSIFICATION | BLEEDING COMPLICATIONS | TRIAL | IMPACT | CLOPIDOGREL | ACADEMIC RESEARCH CONSORTIUM | PRASUGREL | INTERVENTION | Purinergic P2Y Receptor Antagonists - administration & dosage | Tablets | Humans | Middle Aged | Male | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Time Factors | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Prasugrel Hydrochloride - administration & dosage | Drug Therapy, Combination | Ticagrelor | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Treatment Outcome | Prasugrel Hydrochloride - adverse effects | Adenosine - administration & dosage | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Medication Adherence | Adenosine - analogs & derivatives | Clopidogrel | Hemorrhage - chemically induced | Drug Substitution | Drug Combinations | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study
by Motovska, Zuzana and Hlinomaz, Ota and Miklik, Roman and Hromadka, Milan and Varvarovsky, Ivo and Dusek, Jaroslav and Knot, Jiri and Jarkovsky, Jiri and Kala, Petr and Rokyta, Richard and Tousek, Frantisek and Kramarikova, Petra and Majtan, Bohumil and Simek, Stanislav and Branny, Marian and Mrozek, Jan and Cervinka, Pavel and Ostransky, Jiri and Widimsky, Petr and PRAGUE-18 Study Grp and PRAGUE-18 Study Group
Circulation, ISSN 0009-7322, 11/2016, Volume 134, Issue 21, pp. 1603 - 1612
BACKGROUND:No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher... 
percutaneous coronary intervention | ticagrelor | prasugrel hydrochloride | treatment outcome | safety | myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | ST-SEGMENT-ELEVATION | EFFICACY | GUIDELINES | TRIAL | CLOPIDOGREL | TREATMENT PATTERNS | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | OUTCOMES | ARTERY-DISEASE | Humans | Middle Aged | Adenosine - administration & dosage | Prasugrel Hydrochloride - therapeutic use | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Percutaneous Coronary Intervention - methods | Adenosine - analogs & derivatives | Adenosine - therapeutic use | Myocardial Infarction - pathology | Platelet Aggregation Inhibitors - administration & dosage | Adult | Female | Aged | Prasugrel Hydrochloride - administration & dosage | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Heart attack | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Crushed Prasugrel Tablets in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention the CRUSH Study
by Rollini, Fabiana and Franchi, Francesco and Hu, Jenny and Kureti, Megha and Aggarwal, Niti and Durairaj, Ashwin and Park, Yongwhi and Seawell, Michael and Cox-Alomar, Pedro and Zenni, Martin M and Guzman, Luis A and Suryadevara, Siva and Antoun, Patrick and Bass, Theodore A and Angiolillo, Dominick J
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2016, Volume 67, Issue 17, pp. 1994 - 2004
Background Platelet inhibitory effects induced by oral P2Y receptor antagonists are delayed in patients with ST-segment elevation myocardial infarction (STEMI)... 
crushed tablet | pharmacodynamic | pharmacokinetic | platelets | Prospective Studies | Tablets | Humans | Middle Aged | Male | ST Elevation Myocardial Infarction - therapy | Platelet Aggregation | Platelet Aggregation Inhibitors - blood | Receptors, Purinergic P2Y12 - blood | Platelet Aggregation Inhibitors - administration & dosage | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - administration & dosage | Prasugrel Hydrochloride - pharmacokinetics | Percutaneous Coronary Intervention | Prasugrel Hydrochloride - blood | Transluminal angioplasty | Medicine, Experimental | Medical research | Cardiology | Studies | Anticoagulants | Aspirin | Heart attacks | Blood platelets | Bioavailability | Acute coronary syndromes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effect of grapefruit juice on the bioactivation of prasugrel
by Holmberg, Mikko T and Tornio, Aleksi and Hyvärinen, Hanna and Neuvonen, Mikko and Neuvonen, Pertti J and Backman, Janne T and Niemi, Mikko
British Journal of Clinical Pharmacology, ISSN 0306-5251, 07/2015, Volume 80, Issue 1, pp. 139 - 145
AimsThe P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong... 
grapefruit juice | prasugrel | cytochrome P450 3A4 | drug interaction | Prasugrel | Drug interaction | Grapefruit juice | Cytochrome P450 3A4 | METABOLITES | CYTOCHROMES P450 | INCREASES | HUMANS | PHARMACODYNAMICS | CLOPIDOGREL | INHIBITION | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | FELODIPINE | PHARMACOLOGY & PHARMACY | Beverages - adverse effects | Prasugrel Hydrochloride - pharmacology | Citrus paradisi - adverse effects | Food-Drug Interactions | Humans | Male | Prodrugs - metabolism | Cross-Over Studies | Platelet Aggregation Inhibitors - blood | Young Adult | Prasugrel Hydrochloride - metabolism | Prodrugs - pharmacokinetics | Platelet Aggregation Inhibitors - pharmacology | Female | Activation, Metabolic - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Platelet Aggregation Inhibitors - metabolism | Blood Platelets - drug effects | Prasugrel Hydrochloride - pharmacokinetics | Prasugrel Hydrochloride - blood | Hydrolysis | Metabolites | Cytochrome P-450 | Fruit juices | Index Medicus | Drug Interactions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text P2Y 12 Antagonism promises and challenges
by Michelson, Alan D
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 03/2008, Volume 28, Issue 3, pp. s33 - s38
Prasugrel | AZD6140 | Cangrelor | Clopidogrel | Platelets
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
by Umemura, Kazuo and Ikeda, Yasuhiko and Kondo, Kazunao
Drug Metabolism and Pharmacokinetics, ISSN 1347-4367, 08/2016, Volume 31, Issue 4, pp. 285 - 291
This randomized double-blind and placebo-controlled study assessed the pharmacodynamics and pharmacokinetics of prasugrel in healthy adult Japanese male... 
Prasugrel | Inhibition of platelet aggregation | Japanese healthy subjects | Pharmacokinetics | P2Y12 receptor antagonist | receptor antagonist | P2Y | ASPIRIN-TREATED PATIENTS | TRITON-TIMI 38 | CS-747 PRASUGREL | CLOPIDOGREL | INHIBITION | PHARMACOLOGY | HUMAN PLATELET-AGGREGATION | PHARMACOLOGY & PHARMACY | CORONARY-ARTERY-DISEASE | THIENOPYRIDINE ANTIPLATELET AGENT | ACTIVE METABOLITE | Prasugrel Hydrochloride - pharmacology | Double-Blind Method | Humans | Japan | Male | Prasugrel Hydrochloride - adverse effects | Healthy Volunteers | Young Adult | Platelet Aggregation Inhibitors - pharmacology | Adult | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - pharmacokinetics | Platelet Aggregation Inhibitors - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Prasugrel in critically ill patients
by Schoergenhofer, Christian and Hobl, Eva-Luise and Staudinger, Thomas and Speidl, Walter S and Heinz, Gottfried and Siller-Matula, Jolanta and Zauner, Christian and Reiter, Birgit and Kubica, Jacek and Jilma, Bernd
Thrombosis and Haemostasis, ISSN 0340-6245, 06/2017, Volume 117, Issue 8, pp. 1582 - 1587
Summary While prasugrel is indicated for the treatment of myocardial infarction, its effects in the most severely affected patients requiring intensive care is... 
Cellular Haemostasis and Platelets | Antiplatelet drugs | Pharmacodynamics | Pharmacokinetics | Intensive care unit | Platelet function | TICAGRELOR | pharmacodynamics | platelet function | ANTIPLATELET | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC-ARREST | INHIBITION | THERAPEUTIC HYPOTHERMIA | pharmacokinetics | PERIPHERAL VASCULAR DISEASE | intensive care unit | TREATMENT PLATELET REACTIVITY | HEMATOLOGY | ARTERY-DISEASE | Activation, Metabolic | Humans | Middle Aged | Critical Illness | Male | Microfilament Proteins - blood | Drug Monitoring - methods | Platelet Aggregation Inhibitors - blood | Austria | Phosphoproteins - blood | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - administration & dosage | Blood Platelets - drug effects | Prasugrel Hydrochloride - pharmacokinetics | Drug Resistance | Platelet Aggregation Inhibitors - adverse effects | Cell Adhesion Molecules - blood | Treatment Outcome | Prasugrel Hydrochloride - adverse effects | Biomarkers - blood | Blood Platelets - metabolism | Prasugrel Hydrochloride - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome
by Bernlochner, Isabell and Goedel, Alexander and Plischke, Conny and Schupke, Stefanie and Haller, Bernhard and Schulz, Christoph and Mayer, Katharina and Morath, Tanja and Braun, Siegmund and Schunkert, Heribert and Siess, Wolfgang and Kastrati, Adnan and Laugwitz, Karl-Ludwig
European Heart Journal, ISSN 0195-668X, 2015, Volume 36, Issue 45, pp. 3202 - 3210
Aims The influence of reticulated platelets (RPs) on platelet inhibition by ticagrelor when compared with prasugrel is unknown. We aimed to determine the... 
Reticulated platelets † Platelet aggregation † Ticagrelor † Prasugrel † Acute coronary syndrome | Prasugrel | Reticulated platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | CLOPIDOGREL | INHIBITION | TURNOVER | REACTIVITY | Platelet aggregation | Ticagrelor | Acute coronary syndrome | ASPIRIN | Prospective Studies | P-Selectin - metabolism | Humans | Male | Treatment Outcome | Hospitalization | Acute Coronary Syndrome - blood | Prasugrel Hydrochloride - therapeutic use | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine - therapeutic use | Female | Aged | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
by Heeney, Matthew M and Hoppe, Carolyn C and Abboud, Miguel R and Inusa, Baba and Kanter, Julie and Ogutu, Bernhards and Brown, Patricia B and Heath, Lori E and Jakubowski, Joseph A and Zhou, Chunmei and Zamoryakhin, Dmitry and Agbenyega, Tsiri and Colombatti, Raffaella and Hassab, Hoda M and Nduba, Videlis N and Oyieko, Janet N and Robitaille, Nancy and Segbefia, Catherine I and Rees, David C and DOVE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 02/2016, Volume 374, Issue 7, pp. 625 - 635
In an effort to reduce the rate of sickle cell crises and acute chest syndrome, a trial compared prasugrel with placebo in patients 2 through 17 years of age... 
MEDICINE, GENERAL & INTERNAL | ANTIPLATELET AGENT | MULTICENTER | RISK-FACTORS | PAIN | CLOPIDOGREL | CLINICAL-TRIALS | DISEASE | ANEMIA | PLATELET ACTIVATION | YOUNG-CHILDREN | Peripheral Vascular Diseases - prevention & control | Acute Chest Syndrome - etiology | Double-Blind Method | Pain - prevention & control | Administration, Oral | Anemia, Sickle Cell - complications | Humans | Child, Preschool | Male | Anemia, Sickle Cell - drug therapy | Prasugrel Hydrochloride - adverse effects | Prasugrel Hydrochloride - therapeutic use | Peripheral Vascular Diseases - etiology | Adolescent | Pain - etiology | Female | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Acute Chest Syndrome - prevention & control | Child | Platelet Aggregation Inhibitors - adverse effects | Care and treatment | Sickle cell anemia | Occlusion | Adolescence | Anemia | Clinical trials | Patients | Hemorrhage | Thrombosis | Pain | Blood platelets | Cell adhesion | Children | Sickle cell disease | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights